HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

HARVARD BIOSCIENCE INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$8.09+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $36.62M
P/E (TTM): –
Dividend yield: –

HARVARD BIOSCIENCE INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	87	94	112	113	119	102	116	121	77	105	109	109	105	111	109	108	86
Cost of Revenue	37	39	46	53	51	44	52	58	38	56	60	59	57	59	59	56	44
Gross Profit	50	55	66	61	68	58	64	63	39	48	49	49	48	52	50	52	42
Research & Development	8.83	10	12	12	11	8.69	11	11	5.65	5.39	6.42	4.88	4.15	4.34	3.87	4.67	4.40
Selling, General & Admin	37	44	47	50	49	43	46	46	33	41	40	35	35	36	35	34	27
Selling & Marketing	19	22	24	25	25	20	23	24	15	20	21	18	17	18	17	16	12
General & Administrative	18	21	23	24	24	24	23	21	18	21	20	17	18	18	18	18	15
Operating Expenses	98	61	64	68	66	58	64	62	40	51	50	43	46	45	42	42	34
Operating Income	-49	-6.21	1.89	-6.93	2.07	0.22	0.38	0.98	-0.64	-3.00	-1.71	6.62	1.54	7.83	8.41	10	8.06
Interest Expense	1.30	0.80	–	–	–	–	–	5.37	0.71	0.64	0.85	0.99	0.96	0.58	0.75	0.68	0.28
Other Non-Operating Income	-8.81	-5.45	-4.45	-2.25	-2.21	-7.51	-5.88	-8.96	-1.99	-0.08	-1.90	-2.20	-1.10	-0.94	-1.54	-0.66	1.76
Merger & Restructuring Charges	0.20	0.80	0.39	2.39	1.28	2.03	1.35	–	0	0.00	0.79	1.03	2.15	0.31	0.47	0.50	0.52
Asset Impairment Charges	48	0	0	0	0	0	1.46	–	0	0.68	0	0	–	–	–	–	–
Gain (Loss) on Investments	0	-1.59	-0.63	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0	0.40	0	–	–	–	1.25	0.01	0	-0.03	0.81	0	0.02	0.02	0.02	-0.01
Legal Settlements	–	–	0	0.23	0	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-57	-12	-2.56	-9.18	-0.14	-7.29	-5.50	-7.98	-2.62	-3.08	-3.61	4.42	0.44	6.89	6.87	9.56	9.81
Income Tax Expense	-0.69	0.74	0.86	0.34	0.15	0.52	-0.82	-3.68	-0.61	1.23	15	2.06	-0.29	2.40	1.58	-9.45	2.67
Income from Continuing Operations	–	–	–	–	–	–	-4.69	-4.30	-2.02	–	-19	2.36	0.72	4.49	5.29	19	7.14
Income from Discontinued Operations	–	–	–	–	–	–	–	1.38	1.15	–	0	0	-2.55	-2.12	-1.48	0	0.09
Net Income	-57	-12	-3.42	-9.52	-0.29	-7.81	-4.69	-2.92	-0.87	-4.31	-19	2.36	-1.83	2.37	3.81	19	7.23
EPS (Basic)(per share)	-12.80	-2.80	-0.80	-2.30	-0.10	-2.00	-1.20	-0.80	-0.20	-1.30	-5.70	0.70	-0.60	0.90	1.40	6.60	2.40
EPS (Diluted)(per share)	-12.80	-2.80	-0.80	-2.30	-0.10	-2.00	-1.20	-0.80	-0.20	-1.30	-5.70	0.70	-0.60	0.80	1.30	6.50	2.40
Shares Outstanding (Basic, Weighted)(shares)	4.44	4.35	4.24	4.14	4.03	3.86	3.78	3.65	3.48	3.42	3.36	3.22	3.04	2.88	2.85	2.90	2.96
Shares Outstanding (Diluted, Weighted)(shares)	4.44	4.35	4.24	4.14	4.03	3.86	3.78	3.65	3.48	3.42	3.36	3.32	3.19	2.98	2.98	2.94	2.99
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	12	13	14	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 58.2%
Operating margin: -0.3%
Net margin: -11.9%
Return on equity, FY2025: -147.1%

Financial strength

Current ratio: 1.87
Debt to equity: 4.94
Debt to assets: 48.1%
Cash to current liabilities: 26.2%

Valuation

P/E ratio: –
Price to sales: 0.42
Price to book: 4.94
Dividend yield: –